Julie Dietrich1, Jeannine Alivojvodic2, Irene Seliverstov3, Marilyn Metcalf4, Kelsey Jakee5. 1. 1 Development Design Center, Global Development, Amgen Inc, Thousand Oaks, CA, USA. 2. 2 Drug Development Operations, Global Clinical Trial Management, Allergan, Irvine, CA, USA. 3. 3 Product Development, Global Clinical Operations, Genentech, South San Francisco, CA, USA. 4. 4 Global Medical, GSK, Research Triangle Park, NC, USA. 5. 5 Advisory Services, Kinapse Inc, New York, NY, USA.
Abstract
BACKGROUND: Researchers are increasingly motivated to move toward patient-centric drug development. TransCelerate has identified improved "information exchange" as an important component of creating a more satisfying clinical trial experience for patients and their health care professionals (HCPs). METHODS: Patients, sponsors, sites, and HCPs were engaged through surveys, interviews, and/or advisory boards to capture the current status of information exchange and identify possible future practices between the major stakeholders within the clinical research ecosystem. RESULTS: Data suggest that patients have numerous desires and preferences for information exchange during their clinical trial journey that are not commonly met. Various opportunities exist to improve the clinical trial participants' experiences by improving information exchange practices across various stages of the participant's journey. CONCLUSIONS: A shift in industry focus toward more comprehensive information exchange with trial participants has the potential to positively impact many patients.
BACKGROUND: Researchers are increasingly motivated to move toward patient-centric drug development. TransCelerate has identified improved "information exchange" as an important component of creating a more satisfying clinical trial experience for patients and their health care professionals (HCPs). METHODS:Patients, sponsors, sites, and HCPs were engaged through surveys, interviews, and/or advisory boards to capture the current status of information exchange and identify possible future practices between the major stakeholders within the clinical research ecosystem. RESULTS: Data suggest that patients have numerous desires and preferences for information exchange during their clinical trial journey that are not commonly met. Various opportunities exist to improve the clinical trial participants' experiences by improving information exchange practices across various stages of the participant's journey. CONCLUSIONS: A shift in industry focus toward more comprehensive information exchange with trial participants has the potential to positively impact many patients.
Entities:
Keywords:
TransCelerate; clinical research; drug development; health care; patient engagement